Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 2Psoriasis 1Prostatic Neoplasms 1Precancerous Conditions 1Paget's Disease, Mammary 1Osteoarthritis 1Obesity 1Neoplasms 1Neoplasm, Residual 1Fatigue 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Cancer Cachexia 1Breast Carcinoma In Situ 1Barrett Esophagus 1Autoimmune Diseases 1Arthritis, Rheumatoid 1Aggressive Periodontitis 1

Interventions

Carboplatin 235Pemetrexed 214Paclitaxel 160Cisplatin 150pembrolizumab 145Erlotinib Hydrochloride 141Docetaxel 133Gemcitabine 94Bevacizumab 85Nivolumab 72Radiotherapy 62atezolizumab 40Radiosurgery 37Afatinib 37osimertinib 35130-nm albumin-bound paclitaxel 35Cetuximab 34durvalumab 33Ipilimumab 32Gefitinib 31Albumin-Bound Paclitaxel 29Vinorelbine 23Taxes 22Etoposide 20Crizotinib 19Radiation 17Sorafenib 16Cyclophosphamide 16Dexamethasone 15Magnetic Resonance Spectroscopy 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Non-Small-Cell Lung × Docosahexaenoic Acids × Clear all
NCT00243867 2025-08-01

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

American Regent, Inc.

Phase 3 Completed
518 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡